Alliance Global Partners Raises Soligenix Inc. Price Target Amid Clinical Progress

Soligenix Inc. (NASDAQ: SNGX), a biopharmaceutical company specializing in rare diseases, has seen its price target raised to $10 per share by Alliance Global Partners (AGP), which also maintained its Buy rating for the company. This adjustment reflects the growing valuation of HyBryte(TM), Soligenix's treatment for early-stage cutaneous T cell lymphoma (CTCL), and the potential of SGX945, a therapy for Behçet’s disease.

The report highlights the progress of Soligenix's phase 3 FLASH2 trial, expected to announce topline results next year. This trial builds on the initial FLASH study, extending the treatment duration to 18 weeks from six. Additionally, Soligenix has reported promising data from a phase 2a study of SGX945 for Behçet’s disease, showing efficacy comparable or superior to existing treatments.

AGP's valuation of Soligenix at $10 per share is based on projected launches and sales of HyBryte and SGX945, alongside potential government contracts for RiVax(R), a ricin toxin vaccine candidate. The report underscores the company's potential to address unmet medical needs in rare diseases, with significant implications for patients and investors alike.

For more details on the report, visit https://ibn.fm/6zX9x.